Zealand Pharma A/S Total Assets
Zealand Pharma A/S total assets. Based on the latest financial reports, Zealand Pharma A/S (ZEAL) holds total assets worth Dkr16.46 Billion DKK (≈ $2.58 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ZEAL company net worth for the company's overall valuation and market capitalisation.
Total Assets of Zealand Pharma A/S (2007–2025)
Total assets of Zealand Pharma A/S from 2007 to 2025. This chart illustrates how Zealand Pharma A/S's total assets have evolved over time, based on quarterly financial data. See Zealand Pharma A/S share price for real-time trading data and today's change.
Zealand Pharma A/S - Asset Composition Analysis
Zealand Pharma A/S Total Assets Breakdown (December 2025)
Zealand Pharma A/S total assets breakdown as of December 2025. Zealand Pharma A/S's total assets of Dkr16.46 Billion consist of 95.2% current assets and 4.8% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 27.8% |
| Accounts Receivable | Dkr319.69 Million | 1.9% |
| Inventory | Dkr0.00 | 0.0% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr44.97 Million | 0.3% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Zealand Pharma A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Zealand Pharma A/S to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zealand Pharma A/S's current assets represent 95.2% of total assets in 2025, a decrease from 95.5% in 2007.
- Cash Position: Cash and equivalents constituted 27.8% of total assets in 2025, down from 93.5% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
Zealand Pharma A/S Competitors by Total Assets
Key competitors of Zealand Pharma A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Zealand Pharma A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.57 | 21.14 | 5.18 |
| Quick Ratio | 23.57 | 21.11 | 4.91 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr15.01 Billion | Dkr8.12 Billion | Dkr1.48 Billion |
Zealand Pharma A/S - Advanced Valuation Insights
This section examines the relationship between Zealand Pharma A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.81 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | 73.2% |
| Total Assets | Dkr16.46 Billion |
| Market Capitalization | $2.58 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Zealand Pharma A/S's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Zealand Pharma A/S's assets grew by 73.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zealand Pharma A/S (2007–2025)
The table below shows the annual total assets of Zealand Pharma A/S from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr16.46 Billion ≈ $2.58 Billion |
+73.18% |
| 2024-12-31 | Dkr9.51 Billion ≈ $1.49 Billion |
+380.08% |
| 2023-12-31 | Dkr1.98 Billion ≈ $309.78 Million |
+28.59% |
| 2022-12-31 | Dkr1.54 Billion ≈ $240.91 Million |
-25.53% |
| 2021-12-31 | Dkr2.07 Billion ≈ $323.50 Million |
+7.43% |
| 2020-12-31 | Dkr1.92 Billion ≈ $301.12 Million |
+20.32% |
| 2019-12-31 | Dkr1.60 Billion ≈ $250.26 Million |
+30.06% |
| 2018-12-31 | Dkr1.23 Billion ≈ $192.41 Million |
+66.81% |
| 2017-12-31 | Dkr737.24 Million ≈ $115.35 Million |
+6.13% |
| 2016-12-31 | Dkr694.63 Million ≈ $108.68 Million |
+9.44% |
| 2015-12-31 | Dkr634.69 Million ≈ $99.30 Million |
+6.36% |
| 2014-12-31 | Dkr596.76 Million ≈ $93.37 Million |
+72.02% |
| 2013-12-31 | Dkr346.91 Million ≈ $54.28 Million |
-33.59% |
| 2012-12-31 | Dkr522.40 Million ≈ $81.73 Million |
+11.27% |
| 2011-12-31 | Dkr469.48 Million ≈ $73.45 Million |
+4.20% |
| 2010-12-31 | Dkr450.55 Million ≈ $70.49 Million |
+183.94% |
| 2009-12-31 | Dkr158.68 Million ≈ $24.83 Million |
-29.55% |
| 2008-12-31 | Dkr225.24 Million ≈ $35.24 Million |
-14.48% |
| 2007-12-31 | Dkr263.37 Million ≈ $41.21 Million |
-- |
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treat… Read more